Amedisys introduces advanced molecular testing nationwide

BATON ROUGE – Amedisys, Inc. (NASDAQ: NASDAQ:), a home health care provider, has announced a nationwide rollout of advanced molecular testing in collaboration with Patient Choice Laboratories. This new initiative aims to enhance infection diagnosis and treatment in home healthcare by rapidly identifying pathogens in urine, respiratory, and wound infections.

Cyndi Shook, Amedisys’ Senior Vice President of Clinical Operations, emphasized the importance of this advancement in improving patient care quality. The introduction of molecular testing is expected to allow for more accurate and timely treatment plans, tailored to individual patient needs.

The collaboration with Patient Choice Laboratories is intended to provide clinical decision support, with Brad Moss, President at Patients Choice Laboratories, highlighting the benefits of targeted and successful treatments. Thomas Payne, Chief Operations Officer at Patients Choice Laboratories, pointed out the critical nature of quick turnaround times in treating infections, especially among the elderly, citing CDC data on infectious disease-related deaths.

Barbara Andazola, Vice President of Clinical Practice, Strategy and Programs at Amedisys, reiterated the company’s commitment to exceptional care and patient outcomes. The integration of molecular testing into Amedisys’ protocols is part of its strategy to reduce infection impacts and prevent hospitalizations.

Amedisys has ensured the integration of molecular testing into its care centers through comprehensive protocols and training. The company, founded in 1982, operates in 37 states and the District of Columbia, with approximately 19,000 employees serving nearly 470,000 patients annually.

This information is based on a press release statement from Amedisys, Inc.

InvestingPro Insights

Amedisys, Inc. (NASDAQ: AMED), while expanding its healthcare services with advanced molecular testing, also presents an interesting profile for investors. With a market capitalization of approximately $3.06 billion and a P/E ratio (adjusted for the last twelve months as of Q3 2023) standing at 17.94, the company reflects a valuation that aligns with its growth prospects. This valuation is particularly noteworthy considering the InvestingPro Tip that Amedisys is trading at a high earnings multiple, which could suggest investor confidence in the company’s future profitability.

Another InvestingPro Tip indicates that Amedisys generally trades with low price volatility, which may appeal to investors looking for stability in their stock portfolio. Coupled with analysts’ predictions that the company will be profitable this year, and a track record of profitability over the last twelve months, Amedisys appears to be on a solid financial footing. This is further supported by a revenue growth of 0.32% over the last twelve months as of Q3 2023, indicating a steady financial performance.

For investors interested in deeper analytics and additional tips, Amedisys boasts 4 more InvestingPro Tips available on InvestingPro. These insights could be particularly useful for evaluating the company’s long-term investment potential, such as its high return over the last decade and the fact that it does not pay a dividend to shareholders, which might influence reinvestment strategies.

For those considering an InvestingPro+ subscription, use coupon code SFY24 to get an additional 10% off a 2-year subscription, or SFY241 to get an additional 10% off a 1-year subscription. These offers provide access to a wealth of financial data and expert analysis to guide investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.